CN116139108A - 一种脂质递送系统及其所构成的类病毒结构疫苗 - Google Patents
一种脂质递送系统及其所构成的类病毒结构疫苗 Download PDFInfo
- Publication number
- CN116139108A CN116139108A CN202310436870.2A CN202310436870A CN116139108A CN 116139108 A CN116139108 A CN 116139108A CN 202310436870 A CN202310436870 A CN 202310436870A CN 116139108 A CN116139108 A CN 116139108A
- Authority
- CN
- China
- Prior art keywords
- lipid
- vaccine
- virus
- mrna
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 77
- 229960005486 vaccine Drugs 0.000 title claims abstract description 66
- 241000726445 Viroids Species 0.000 title claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 38
- 239000012528 membrane Substances 0.000 claims abstract description 16
- 239000007853 buffer solution Substances 0.000 claims abstract description 10
- 108010008595 sarcoma-associated antigen S1 Proteins 0.000 claims abstract description 8
- 108020004999 messenger RNA Proteins 0.000 claims abstract 9
- -1 2- (2-hydroxyethoxy) ethyl Chemical group 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 239000002105 nanoparticle Substances 0.000 claims description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 12
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- HSBMBJDVXFRTTD-UHFFFAOYSA-N C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC Chemical compound C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC HSBMBJDVXFRTTD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 239000004005 microsphere Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- KDLSKKYZXNKGTK-LQDDAWAPSA-M trimethyl-[(z)-2-[(z)-octadec-9-enoyl]-4-oxohenicos-12-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)CC(C[N+](C)(C)C)C(=O)CCCCCCC\C=C/CCCCCCCC KDLSKKYZXNKGTK-LQDDAWAPSA-M 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 3
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 26
- 102000036639 antigens Human genes 0.000 abstract description 26
- 241001678559 COVID-19 virus Species 0.000 abstract description 20
- 108700021021 mRNA Vaccine Proteins 0.000 abstract description 13
- 229940126582 mRNA vaccine Drugs 0.000 abstract description 13
- 239000000427 antigen Substances 0.000 abstract description 10
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 abstract description 6
- 230000006698 induction Effects 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 6
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- 101710139375 Corneodesmosin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229950004354 phosphorylcholine Drugs 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101710193484 S-antigen protein Proteins 0.000 description 2
- 101150027674 S1 gene Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310436870.2A CN116139108B (zh) | 2023-04-23 | 2023-04-23 | 一种脂质递送系统及其所构成的类病毒结构疫苗 |
US18/228,700 US11911460B1 (en) | 2023-04-23 | 2023-08-01 | Lipid delivery system and virus-like structure (VLS) vaccine constructed therefrom |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310436870.2A CN116139108B (zh) | 2023-04-23 | 2023-04-23 | 一种脂质递送系统及其所构成的类病毒结构疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116139108A true CN116139108A (zh) | 2023-05-23 |
CN116139108B CN116139108B (zh) | 2023-08-01 |
Family
ID=86341097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310436870.2A Active CN116139108B (zh) | 2023-04-23 | 2023-04-23 | 一种脂质递送系统及其所构成的类病毒结构疫苗 |
Country Status (2)
Country | Link |
---|---|
US (1) | US11911460B1 (zh) |
CN (1) | CN116139108B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112641935A (zh) * | 2020-10-15 | 2021-04-13 | 百葵锐(天津)生物科技有限公司 | 一种含颗粒载体的亚单位疫苗及其应用 |
CN113402405A (zh) * | 2021-04-08 | 2021-09-17 | 厦门赛诺邦格生物科技股份有限公司 | 一种阳离子脂质、含该阳离子脂质的脂质体、含该脂质体的核酸药物组合物及其制剂和应用 |
WO2022101469A1 (en) * | 2020-11-16 | 2022-05-19 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
CN114617980A (zh) * | 2022-03-09 | 2022-06-14 | 广州国家实验室 | 可电离脂质纳米颗粒及其应用 |
CN114729373A (zh) * | 2022-01-27 | 2022-07-08 | 深圳市瑞吉生物科技有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
WO2023283412A1 (en) * | 2021-07-09 | 2023-01-12 | Atossa Therapeutics, Inc. | Compositions and methods to increase coronavirus immune response |
CN115590836A (zh) * | 2022-09-27 | 2023-01-13 | 浙江大学(Cn) | 一种提高mRNA疫苗诱导免疫应答能力的脂质纳米颗粒及其应用 |
WO2023043933A1 (en) * | 2021-09-15 | 2023-03-23 | Verndari, Inc. | Stabilized lipid nanoparticle mrna compositions and uses thereof |
CN115843330A (zh) * | 2020-04-22 | 2023-03-24 | 辉瑞公司 | 冠状病毒疫苗 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021142336A1 (en) * | 2020-01-08 | 2021-07-15 | Puretech Lyt, Inc. | Vesicle compositions for oral delivery |
-
2023
- 2023-04-23 CN CN202310436870.2A patent/CN116139108B/zh active Active
- 2023-08-01 US US18/228,700 patent/US11911460B1/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115843330A (zh) * | 2020-04-22 | 2023-03-24 | 辉瑞公司 | 冠状病毒疫苗 |
CN112641935A (zh) * | 2020-10-15 | 2021-04-13 | 百葵锐(天津)生物科技有限公司 | 一种含颗粒载体的亚单位疫苗及其应用 |
WO2022101469A1 (en) * | 2020-11-16 | 2022-05-19 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
CN113402405A (zh) * | 2021-04-08 | 2021-09-17 | 厦门赛诺邦格生物科技股份有限公司 | 一种阳离子脂质、含该阳离子脂质的脂质体、含该脂质体的核酸药物组合物及其制剂和应用 |
CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
WO2023283412A1 (en) * | 2021-07-09 | 2023-01-12 | Atossa Therapeutics, Inc. | Compositions and methods to increase coronavirus immune response |
WO2023043933A1 (en) * | 2021-09-15 | 2023-03-23 | Verndari, Inc. | Stabilized lipid nanoparticle mrna compositions and uses thereof |
CN114729373A (zh) * | 2022-01-27 | 2022-07-08 | 深圳市瑞吉生物科技有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
CN114617980A (zh) * | 2022-03-09 | 2022-06-14 | 广州国家实验室 | 可电离脂质纳米颗粒及其应用 |
CN115590836A (zh) * | 2022-09-27 | 2023-01-13 | 浙江大学(Cn) | 一种提高mRNA疫苗诱导免疫应答能力的脂质纳米颗粒及其应用 |
Non-Patent Citations (2)
Title |
---|
YONG-QIANG DENG ET AL.: "Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters", CELL RESEARCH, vol. 32, no. 4, pages 375 - 382, XP037789509, DOI: 10.1038/s41422-022-00630-0 * |
张秀奇: "PEG-脂质ALC-0159在大鼠体内的药代动力学研究", 中国优秀硕士学位论文全文数据库 (医药卫生科技辑), pages 079 - 376 * |
Also Published As
Publication number | Publication date |
---|---|
US11911460B1 (en) | 2024-02-27 |
CN116139108B (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110714015B (zh) | 一种mRNA狂犬病疫苗 | |
Li et al. | Non-viral strategies for delivering genome editing enzymes | |
JP2015500826A (ja) | トランスフェリンペプチドを有するエキソソーム | |
Kumar et al. | Exosomes: natural carriers for siRNA delivery | |
WO2022160709A1 (zh) | 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用 | |
WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
CN116133640A (zh) | 脂质纳米颗粒 | |
CN114277039B (zh) | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 | |
CN116139108B (zh) | 一种脂质递送系统及其所构成的类病毒结构疫苗 | |
CN108424437B (zh) | 一种递送分子及纳米颗粒、制备方法、用途 | |
CN115998714B (zh) | 一种脂质纳米颗粒、递送系统及递送系统的制备方法 | |
CA3035356C (en) | Nucleic acid-peptide capsule complexes | |
CN110638787B (zh) | 一种防治鼻咽癌的亚单位纳米疫苗及其制备方法 | |
CN117024532A (zh) | 共负载CpG、MPLA双佐剂和EB病毒糖蛋白的纳米疫苗的制备和应用 | |
KR20210120013A (ko) | 핵산 전달 복합체 | |
CN110772635B (zh) | 流感病毒小体包被的仿生纳米疫苗及其制备方法 | |
CN113637695B (zh) | 靶向刺激体液免疫和细胞免疫的新冠病毒mRNA疫苗 | |
CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
JP2019511566A (ja) | 核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット | |
AU2020103603A4 (en) | An influenza virosome-coated biomimetic nanovaccine and the preparation method | |
CN114159556A (zh) | 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体 | |
US20070258993A1 (en) | Dna-Carrier Conjugate | |
US11298415B2 (en) | Alginate chitosan nanoformulation of OmpA—a Shigella protein subunit | |
WO2024055273A1 (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
CN115927417B (zh) | 无帽线性且无修饰尿苷的mRNA技术平台 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230712 Address after: 650000 No. 2-1, floor 2, building B, Ciba biotechnology innovation center, Longquan Road, Panlong District, Kunming City, Yunnan Province Applicant after: Weirui Biotechnology (Kunming) Co.,Ltd. Applicant after: Shandong weigaolitong Biological Products Co.,Ltd. Address before: 650000 No. 2-1, floor 2, building B, Ciba biotechnology innovation center, Longquan Road, Panlong District, Kunming City, Yunnan Province Applicant before: Weirui Biotechnology (Kunming) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |